BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...methods for using alpha-GAL glycolipids to treat solid tumors. Its compounds are exclusively licensed from Kode Biotech...
...Research LLP University collaborators: University of Massachusetts Medical School , University of Oxford Corporate partners: Kode Biotech Ltd....
...Oncology, Alexandria, Va. Centauri Therapeutics Ltd., Sandwich, U.K. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Kode Biotech Ltd....
BioCentury | Jul 13, 2015
Company News

Kode Biotech, Agalimmune deal

...to the license, injects synthetic animal-antigen mimetics, which incorporate the FSL constructs into primary tumors. Kode Biotech Ltd....
Items per page:
1 - 2 of 2
BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...methods for using alpha-GAL glycolipids to treat solid tumors. Its compounds are exclusively licensed from Kode Biotech...
...Research LLP University collaborators: University of Massachusetts Medical School , University of Oxford Corporate partners: Kode Biotech Ltd....
...Oncology, Alexandria, Va. Centauri Therapeutics Ltd., Sandwich, U.K. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Kode Biotech Ltd....
BioCentury | Jul 13, 2015
Company News

Kode Biotech, Agalimmune deal

...to the license, injects synthetic animal-antigen mimetics, which incorporate the FSL constructs into primary tumors. Kode Biotech Ltd....
Items per page:
1 - 2 of 2